

BIBLIOGRAPHY

Abd Elsalam KA (2003). Bioinformatic tools and guideline for PCR primer design. African J of Biotech.2: 91-95.

Abrahamov A, Elstein D, Gross-Tsur V et al. (1995). Gauchers disease variant characterized by progressive calcification of heart valves and unique genotype. Lancet. 346: 1000-1003.

Adelino T, Martins G, Gomes A, Torres A, Silva D, Xavier V et al. (2012). Biochemical and Molecular Chitotriosidase Profiles in Patients with Gaucher Disease Type 1 in Minas Gerais, Brazil: New Mutation in CHIT1 Gene. JIMD Reports. 85: za 91. DOI 10.1007/8904_2012_184

Adolph KW, Long GL, Winfield S, Ginns EI, Bornstein P. (1995). Structure and organization of the human thrombospondin 3 gene (THBS3). Genomics.27:329–336.

Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P et al. (2010). A method and server for predicting damaging missense mutations. Nat Methods. 7: 248-249.doi: 10.1038/nmeth0410-248.

Aerts J and Hollak C (1997). Plasma and metabolic abnormalities in Gaucher disease. Bailliere's cli haem.10: 691-709.

Aerts J, Boot R, Blommaert E, et al. (1999). Chitotriosidase: applications and features of the enzyme. Gaucher Clin Perspect. 7: 4-8.

Aghion H (1934). La maladie de Gaucher dans l'enfance. These, Faculte de Medicine, Paris.

Aguilera B, Ghauharali-van der Vlugt K, Helmond MT, Out JM, Donker-Koopman WE, Groener JE, et al. (2003). Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitinase. J Biol Chem. 278: 40911-6.

Ahn V, Faull K, Whitelegge J, Fluharty A and Privé G (2003). Crystal structure of

saposin B reveals a dimeric shell for lipid binding. Proc Natl Acad Sci. USA. 100: 38-43.

Alfonso P, Aznarez S, Giralt M, Miguel P & Pilar G & on behalf of Spanish Gaucher's Disease Registry (2007). Mutation analysis and genotype/phenotype relationships of Gaucher disease patients in Spain. J Hum Genet.52: 391-396.

Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W et al. (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25: 3389-3402.

Carriero J, Balwani M, Grosskreutz C, Isola L, Malone A, Scigliano E, et al. (2008). A case report of secondary autograft failure due to Gaucher disease. Am J Hemato.183:937.

Andersson H, Kaplan P, Kacena K, Yee J (2008). Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediat. 122: 1182-1190.

Ankleshwaria C, Mistri M, Bavdekar A, Muranjan M, Dave U, Tamhankar P et al. (2014).Novel mutations in the glucocerebrosidase gene of Indian patients with Gaucher Disease.J of Hum Genet.59: 223-228.

Arai K, Shimaya A, Hiratani N and Ohkuma S (1993).Purification and characterization of lysosomal H (+)-ATPase.An anion-sensitive v-type H (+)-ATPase from rat liver lysosomes. J of Bio Chem. 268: 5649-5660.

Armstrong LC, Komiya T, Bergman BE, Mihara K, Bornstein P. (1997). Metaxinis a component of a preprotein import complex in the outer membrane of the mammalian mitochondrion. J Biol Chem 272:6510–6518.

Aronovich E, Pan D and Whitley C (1996).‘Molecular genetic defect underlying alpha-L-iduronidase pseudodeficiency’.Am J Hum Genet. 58: 75-85.

Aronovich EL, Pan D and Whitley CB. (1996). ‘Molecular genetic defect underlying alpha-L-iduronidase pseudodeficiency’.Am J Hum Genet. 58: 75–85.

Arvio M, Autio S. and Louhiala P (1993).‘Early clinical symptoms and incidence of

aspartylglucosaminuria in Finland'. *Acta Paediatr.* 82: 587-589.

Association of Clinical Cytogeneticists Working Party on Chorionic villi in prenatal diagnosis (1994). Cytogenetic analysis of Chorionic villi for prenatal diagnosis: an ACC collaborative study of UK data. *Prenatal Diag.* 14: 363-379.

Ballabio A and Gieselmann V (2009). Lysosomal disorders: from storage to cellular damage. *Biochim Biophys Acta.* 1793: 684-696.

Bampton E, Goemans C, Niranjan D, Mizushima N and Tolkovsky A (2005). The dynamics of autophagy visualized in live cells: from autophagosome formation to fusion with endo/lysosomes. *Autophagy.* 1: 23-36.

Barneveld RA, Keijzer W, Tegelaers FP, Ginns EI, Geurts van Kessel A, Brady RO, Barranger JA, Tager JM, Galjaard H, Westerveld A, Reuser AJ (1983). Assignment of the gene coding for human beta-glucocerebrosidase to the region q21–q31 of chromosome 1 using monoclonal antibodies. *Hum Genet.* 64:227-231.

Baroe R, Sotgiu S, Musumeci S (2007). Plasma chitotriosidase in health and pathology. *Clin Lab.* 53: 321-33.

Barone R, Pavone V, Nigro F et al. (2000). Extraordinary bone involvement in a Gaucher disease type I patient. *Br J Haematol.* 108: 838-41.

Barranger J and Gins E (1989). Gaucher disease. Scriver C, Sly W, Valle D, (eds). *The Metabolic and Molecular Bases of Inherited Diseases*, McGraw-Hill. New York, NY, USA. 1677-1698.

Beaudet AL, Scriver CR, Sly WS, Valle D (1995). Genetics, biochemistry and molecular basis of variant human phenotypes. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. *The Metabolic and Molecular Bases of Inherited Disease*. New York, NY: McGraw-Hill. 7th ed: 53-118.

Bellettato C and Scarpa M (2010). Pathophysiology of neuropathic lysosomal storage disorders. *J Inher Metab Dis.* 33: 347-362.

Bembi B, Zanatta M, Carrozzi M, et al (1994). Enzyme replacement treatment in type 1 and type 3 Gaucher's disease. *Lancet.* 344: 1679–1682.

Berg-Fussman A, Grace M, Loannou Y and Grabowski G (1993). Human β -glucosidase: N- glycosylation site occupancy and the effect of glycosylation on enzymatic activity. J of Bio Chem. 268: 14861-14866.

Beutler E, Grabowski G. In Scriver CR, Valle D, Beudet A, Sly WS (eds).et al. (2001).Gaucher disease The Metabolic and Molecular Bases of Inherited Disease. New York, NY McGraw-Hill Co. 8th ed: 3635- 3668.

Beutler E (1995a). Gaucher disease, aparadigm for single gene defects. Experientia. 51: 196-197.

Beutler E and Grabowski G (2001).The Metabolic and Molecular Bases of Inherited Disease (eds Scriver, C.R., Sly, W.S., Childs, B., Beaudet, A.L., Valle, D., Kinzler, K.W. & Vogelstein, B), McGraw-Hill Inc, New York, USA. 3635-3668.

Beutler E and Saven A (1990). Misuse of marrow examination in the diagnosis of Gaucher disease. Blood. 76: 646-648.

Beutler E, and Kuhi W (1970).Detection of the defect of Gaucher's disease and its carrier state in peripheral-blood leukocytes.Lancet. i: 612-613.

Beutler E, and Kuhl W (1970).The diagnosis of the adult type of Gaucher's disease and its carrier state by demonstration of deficiency of β -glucosidase activity in peripheral blood leukocytes.J Lab Clin Med.76: 747-755.

Beutler E, Demina A, Gelbart T (1994). Glucocerebrosidase mutations in Gaucher disease. Mol Med. 1:82-92.

Beutler E, Gelbart T (1993).Gaucher disease mutations in non-Jewish patients.Br J Haematol.85:401-405.

Beutler E, Gelbart T (1997). Hematologically important mutations: Gaucher disease. Blood Cells Mol Dis. 23: 2-7.

Beutler E, Gelbart T (1998). Hematologically important mutations: Gaucher disease. Blood Cells Mol Dis. 24: 2-8.

Beutler E, Gelbart T, Kuhl W, Sorge J, West C (1991). Identification of the second

common Jewish Gaucher disease mutation makes possible population-based screening for the heterozygous state. *Proc Natl Acad Sci USA*. 88: 10544-10547.

Beutler E, Grabowski G (1995). Glucosylceramide lipidoses: Gaucher disease. In Scriver CR, Valle D, Beudet A, Sly WS (eds). *The Metabolic and Molecular Bases of Inherited Diseases*. McGraw-Hill. New York, NY, USA. 2641-2670.

Beutler E, Grabowski G (2001). Gaucher disease. In Scriver C, Valle D, Beudet A, Sly W (eds). *The Metabolic and Molecular Bases of Inherited Diseases*, Vol III. McGraw-Hill. New York, NY, USA.

Beutler E, Kuhl W, Trinidad F, Teplitz R, Nadler H (1971). β -Glucosidase activity in homozygotes and heterozygotes for gaucher's disease. *Am J Hum Genet*. 23: 62-66.

Beutler E, Nguyen NJ, Henneberger MW, Smolec JM, McPherson RA, West C, Gelbart T (1993b). Gaucher disease: gene frequencies in the Ashkenazi Jewish population. *Am J Hum Genet*. 52: 85-88.

Beutler, E. and Grabowski, G (2001). 'Gaucher disease', in: Scriver, C.R. et al. (eds), *The Metabolic and Molecular Bases of Inherited Disease*, McGraw-Hill, New York, NY. 8th edn: 3635-3668.

Bisariya V, Mistry P, Liu J, Chaudhari M, Gupta N & Kabra M (2011). The mutation spectrum in Indian patients with Gaucher disease. *Genome Biol*. 12.

Boot R, Renkema G, Strijland A, Zonneveld A and Aerts J (1995). Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages. *J Biol Chem*. 270: 26252-6256.

Boot R, Renkema G, Verhoek M, Strijland A, Blik J, Meule-meester T, Mannens M and Aerts J (1998). "The human chitotriosidase gene. Nature of inherited enzyme deficiency". *J Biol Chem*. 273: 25680-25685.

Bouzas L, Guinarte J, Tutor J (2003). Chitotriosidase activity in plasma and mononuclear and polymononuclear leukocyte populations. *J Clin Lab Anal*. 17: 271-5.

Bradova V, Smid F, Ulrich-Bott B, Roggendorf W et al. (1993). 'Prosaposin deficiency: Further characterization of the sphingolipid activator protein-deficient

sibs. Multiple glycolipid elevations (including lac- tosylceramidosis), partial enzyme deficiencies and ultrastructure of the skin in this generalized sphingolipid storage disease'. Hum Genet. 92: 143-152.

Brady R (1996). Gaucher disease. In Moser H (ed.) Handbook of Clinical Neurology, Amsterdam: Elsevier Science. 123-132.

Brady R, Murray G, Barton N (1994). Modifying exogenous glucocerebrosidase for effective replacement therapy in Gaucher disease. J Inherit Metab Dis. 17: 510-9.

Bright N, Gratian M and Luzio J (2005).Endocytic delivery to lysosomes mediated by concurrent fusion and kissing events in living cells.Curr Biol. 15: 360-365.

Bright N, Reaves B, Mullock B and Luzio J (1997). Dense core lysosomes can fuse with late endosomes and are re-formed from the resultant hybrid organelles. J Cell Sci. 110: 2027-2040.

Brill N (1901). Primary splenomegaly: with a report of three cases occurring in one family. Am J of the Med Sci. 121: 377-392.

Brill N (1904). A case of 'splenomegalie primitif': with involvement of haemopoietic organs. Proceedings of the New York Pathological Society.4: 143-149.

Brill N, Mandlebaum F, Libman E (1905). Primary splenomegaly-gaucher type: report on one of four cases occurring in a single generation of one family. Am J of the Med Sci. 129: 491-504.

Brumshtein B, Salinas P, Peterson B, et al. (2010). Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages. Glycobiol. 20: 24-32.

Bukina TM, Tsvetkova IV (2007).Distribution of mutations of acid beta-D-glucosidase gene (GBA) among 68 Russian patients with Gaucher's disease.Biomed Khim. 53: 593-602.

Burrow T, Barnes S, Grabowski G (2011). Prevalence and management of Gaucher disease. Pediat Health, Med and Therapeutics. 2: 59-73.

Burrow T, Cohen M, Bokulic R, et al. (2007). Gaucher disease: progressive mesenteric and mediastinal lymphadenopathy despite enzyme therapy. *J Pediatr.* 150: 202-206.

Burton B (1998). Inborn errors of metabolism in infancy: a guide to diagnosis. *Pediatr.* 102: E69.

Cao Z, Petroulakis E, Salo T and Triggs-Raine B (1997). 'Benign HEXA mutations, C739T(R247W) and C745T(R249W), cause β -hexosaminidase A pseudodeficiency by reducing the alpha-subunit protein levels'. *J Biol Chem.* 272: 14975-14982.

Cao Z, Petroulakis E, Salo T and Triggs-Raine B. (1997). 'Benign HEXA mutations, C739T(R247W) and C745T(R249W), cause beta- hexosaminidase A pseudodeficiency by reducing the alpha-subunit protein levels'. *J Biol Chem.* 272: 14975–14982.

Chabas A, Cormand B, Grinberg D, et al. (1995). Unusual expression of Gaucher's disease: cardiovascular calcification in three sibs homozygous for the D409H mutation. *J of Med Genet.*32: 740-742.

Chabas A, Giros M and Guardiola A (1991). 'Low β -glucuronidase activity in a healthy member of a family with mucopolysaccharidosis VII'. *J Inherit Metab.*14: 908-914.

Chabas A, Giros ML and Guardiola A. (1991). 'Low b-glucuronidase activity in a healthy member of a family with mucopolysaccharidosis VII', *J. Inherit. Metab. Dis.* 14: 908 – 914.

Chamoles N, Blanco M and Gaggioli D (2001). Fabry disease: Enzymatic diagnosis in dried blood spots on filter paper. *Clinica Chimica Acta.*308: 195-196.

Chamoles N, Blanco M, Gaggioli D et al. (2001). Hurler-like phenotype: Enzymatic diagnosis in dried blood spots on filter paper. *Clinica Chimica Acta.*47: 2098-2102.

Charrow J, et al. (2000). The Gaucher registry: demographics and disease characteristics of 1,698 patients with Gaucher disease. *Arch Intern Med.* 160: 2835-

2843.

Chauhan V, Kumar R, Mahesh D, Kashyap R & Thakur S (2013). Adult type 3 Gaucher disease as manifestation of R463C/Rec Nci I mutation: first reported case in the world literature. *J Assoc Phys India*.61: 346-347.

Chi Y, Martinez-Cruz L, Jancarik J, Swanson R, Robertson D and Kim S (1999). Crystal structure of the β -glycosidase from the hyperthermophile *Thermosphaera aggregans*: insights into its activity and thermostability. *FEBS Lett*.445: 375-383.

Chiao B, Glew R, Diven W, and Lee R (1980). Comparison of various β -glucosidase assays used to diagnose Gaucher's disease. *Clin Chim Acta*. 105: 41-50.

Choy FY, Zhang W, Shi HP, Zay A, Campbell T, Tang N, Ferreira P. (2007). Gaucher disease among Chinese patients: review on genotype/phenotype correlation from 29 patients and identification of novel and rare alleles. *Blood Cells Mol Dis*. 38:287–293.

Christomanou H, Chabas A, Pampols T and Guardiola A (1989).‘Activator protein deficient Gaucher's disease.A second patient with the newly identified lipid storage disorder’.*Wien Klin Wochenschr*.67: 999-1003.

Conzelmann E and Sandhoff K (1983). Partial enzyme deficiencies: residual activities and the development of neurological disorders. *Developmental Neurosci*. 6: 58-71.

Cooper A, Church HJ, Wraith JE (2001). Gene symbol: GBA, Disease: Gaucher disease. *Hum Genet*. 108: 82.

Cormand B, Harboe T, Gort L, Campoy C,Blanco M, Chamoles N et al. (1998). Mutation Analysis of Gaucher Disease Patients From Argentina: High Prevalence of the RecNciI Mutation. *Am J of Med Genet*. 80: 343-351.

Cormand B, Vilageliu L, Balcells S, González-Duarte R, Chabás A & Grinberg D (1996).Two novel (1098insA and Y313H) and one rare (R359Q) mutations detected in exon 8 of the β -glucocerebrosidase gene in Gaucher's disease patients. *Hum Mutat*. 7: 272-274.

Cosma M, Pepe S, Annunziata I, Newbold R, et al. (2003). ‘The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases’. *Cell*. 113: 445-456.

Cotran R, Kumar V, Robbins S (1994). Genetic Disorders. *In: Schoen F (ed): Pathologic Basis of Disease*. (5th ed). Philadelphia: WB Saunders Company. 123-170.

Cox T and Cachón-González M (2012).The cellular pathology of lysosomal diseases.*J Pathol*.226: 241-254.

Cox T, Drelichman G, Cravo R, Balwani M, Burrow T, Martins A, et al. Eliglustat versus imiglucerase in patients with Gaucher’s disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. *Lancet*. 385: 2355-2362.

Cox T, Lachmann R, Hollak CEM et al. (2000).Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. *Lancet*. 355: 1481-1485.

D’Azzo A, Andria G, Strisciuglio P and Galjaard H (2001). ‘Galactosialidosis’, in: Scriver, C.R. et al. (eds), *The Metabolic and Molecular Bases of Inherited Diseases*’ (8th edn), McGraw-Hill, New York, NY. 3811-3826.

Dahl M, Doyle A, Olsson K, et al (2015). Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice. *Mol Ther*. 23:835–844.

Dahl N, Lagerstrom M, Erikson A and Pettersson U (1990). Gaucher disease type III (Norrbottnian type) is caused by a single mutation in exon 10 of the glucocerebrosidase gene, *Am J HumGenet*. 47: 275-278.

Daniels L and Glew (1982).B-glucosidase assays in the diagnosis of Gauchers disease. *Clin Chem* 28: 569-577

Dawson G, Kwok B, Nishigaki M and Shen B (1982). Role of serum lipoproteins in the pathogenesis of Gaucher disease. In Desnick R, Gatt S and Grabowski G (eds) *Gaucher disease: a century of Delineation and research* New York: Alan R Liss.

De Duve C and Wattiaux R (1966).Functions of lysosomes.*Annual Review of*

Physio.28: 435-492.

De Duve C, Pressman B, Gianetto R, Wattiaux R and Appelmans F (1955). Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue. *Biochem J.* 60: 604-617.

DiazA, MontfortM, CormandB, ZengB, Pastores GM, ChabasA, et al. (2000). On the age of the most prevalent Gaucher disease-causing mutation, N370S. *Am J Hum Genet.* 66: 2014-2015.

Dierks T, Schmidt B, Borissenko L, Peng J, et al. (2003). ‘Multiple sulfatase deficiency is caused by mutations in the gene encoding the human Ca-formylglycine generating enzyme’. *Cell.* 113: 435-444.

Drugan C, Procopciuc L, Jebeleanu G, Sido P, Dussau J, Poenaru L and Caillaud C (2002). Gaucher disease in Romanian patients: incidence of the most common mutations and phenotypic manifestations. *Eu J of Hum Genet.* 10: 511-515.

Dvir H, Harel M, McCarthy A, Toker L, Silman I, Futerman A & Sussman J (2003). X-ray structure of human acid- β -glucosidase, the defective enzyme in Gaucher disease. *EMBO reports.* 4: 703-709

E. Sidransky, D.M. Sherer, E.I. Ginns, (1992). Gaucher disease in the neo-nate: a distinct Gaucher phenotype is analogous to a mouse model created by targeted disruption of the glucocerebrosidase gene. *Pediat Res.* 32: 494-498.

Eiberg H, Den Tandt W (1997). Assignment of human plasma methylumbelliferyl-tetra-N-acetylchitotetraoside hydrolase or chitinase to chromosome 1q by a linkage study. *Hum Genet.* 101: 205-7.

Ellgaard L and Helenius A (2001). ER quality control: towards an understanding at the molecular level. *Curr Opinion in Cell Bio.* 13: 431-437.

Elstein D, Hollak C, Aerts J, et al. (2004). Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. *J Inherit Metab Dis.* 27: 757-766.

Emre S, Gurakan F, Yuce A, Rolf A, Scott R, Ozen H (2008). Molecular analysis

of Turkish Gaucher disease patients: Identification of novel mutations in glucocerebrosidase (GBA) gene. *European J of Med Genet.*51: 315-321.

Erikson A (1986).Gaucher disease- Norbottnian type (III).Neuropaediatric and neurobiological aspects of clinical patterns and treatment. *Acta Paediatr Scandinavica.* 326: S1-S42.

Erikson A, Bembi B and Schiffmann R (1997).Gaucher's Disease (ed. Zimran, A.), Bailliere Tindall, London, UK. 711-723.

Erikson A, Johansson K, Mansson J and Svennerholm L (1993). Enzyme replacement therapy of infantile Gaucher disease. *Neuropediatr.* 24: 237-238.

Eskelinen E, Tanaka Y and Saftig P (2003). At the acidic edge: emerging functions for lysosomal membrane proteins. *Trends in Cell Bio.*13: 137-145.

Eto Y, Ida H (1999).Clinical and molecular characteristics of Japanese Gaucher disease.*Neurochem Res.* 24: 207-211.

Eyal N, Firon N, Wilder S, Kolodny EH, Horowitz M (1991).Three unique base pair changes in a family with Gaucher disease. *Hum Genet.* 87: 328-332.

Eyal N, Wilder S, Horowitz M (1990). Prevalent and rare mutations among Gaucher patients. *Gene.* 96: 277-283.

F Y Choy, W Zhang, H P Shi et al. (2007). Gaucher disease among Chinese patients: review on genotype/phenotype correlation from 29 patients and identification of novel and rare alleles, *Blood Cells Mol Diseases.* 38: 287-293.

Fabrega S, Durand P, Mornon J and Lehn P (2002). The active site of human glucocerebrosidase: structural predictions and experimental validations. *J Soc Biol.*196: 151-160.

Fader C and Colombo M (2009). Autophagy and multivesicular bodies: two closely related partners. *Cell Death Differ.*16: 70-78.

Feroze M, Arvindan K, Jose L (1994). Gaucher's disease among Mappila muslims of Malabar. *Indian J Pathol Microbiol.* 37: 307-311.

Filocamo M and Morrone A (2011). Lysosomal storage disorders: Molecular basis and laboratory testing. Hum Genomics. 5:156-169.

Fiore C, Barone R, Pennisi P, et al. (2002). Bone ultrasonometry, bone density, and turnover markers in type 1 Gaucher disease. J Bone Miner Metab. 20: 34-8.

Freitag F, Kuchemann K and Blumcke S (1971). Hepatic ultrastructure in fucosidosis. Virchows Archiv B. Cell Pathol. 7: 99-113.

Froissart R, Guffon N, Vanier M, Desnick R et al. (2003). 'Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma'. Mol. Genet. Metab. 80: 307 – 314.

Froissart R, Guffon N, Vanier M, Desnick R, et al. (2003). 'Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma'. Mol Genet Metab. 80: 307-314.

Fuller M, Meikle P and Hopwood J (2006). Epidemiology of lysosomal storage diseases: an overview. Oxford: Oxford PharmaGenesis. Chapter 2.

Fusetti F, von Moeller H, Houston D, Rozeboom H, Dijkstra B, Boot R, Aerts J and van Aalten D (2002). J Biol Chem. 277: 25537-25544.

Futerman A and van Meer G (2004). 'The cell biology of lysosomal storage disorders'. Nat Rev Mol Cell Biol. 5: 554-565.

Galjaard H (1980). In Genetic metabolic diseases: early diagnosis and prenatal analysis, Amsterdam, Elsevier North Holland. 790-828.

Gatti R, Lombardo C, Filocamo M, Borrone C, Porro E (1985). Comparative study of 15 lysosomal enzymes in chorionic villi and cultured amniotic fluid cells. Early prenatal diagnosis in seven pregnancies at risk for lysosomal storage diseases. Prenat Diagn. 5: 329-336.

Gaucher PCE (1882). De l'epithelioma primitif de la rate, hypertrophie idiopathique de la rate sans leucemie [academic thesis]. Paris, France.

Ghosh P, Dahms N and Kornfeld S (2003). Mannose 6-phosphate receptors: new

twists in the tale. *Nat Rev Mol Cell Biol.* 4: 202-212.

Gieselmann V, Polten A, Kreysing J and Figura K (1989). ‘Arylsulfatase A pseudodeficiency: Loss of a polyadenylation signal and N-glycosylation site’. *Proc Natl Acad Sci, USA.* 86: 9436-9440.

Ginns EI, Choudary PV, Martin BM, Winfield S, Stubblefield B, Mayor J, Merkle-Lehman D, Murray GJ, Bowers LA, Barranger JA (1984). Isolation of cDNA clones for human beta-glucocerebrosidase using the lambda gt11 expression system. *Biochem Biophys Res Commun.* 123: 574-580.

Glenn D, Gelbart T, Beutler E (1994). Tight linkage of pyruvate kinase (PKLR) and glucocerebrosidase (GBA) genes. *Hum Genet.* 93: 635-638.

Goldblatt J, Sacks S, Beighton P (1978). The orthopedic aspects of Gaucher disease. *Clin Orthop Relat Res.* 137: 208-14.

Goldman A, Jacobs B (1984). Femoral neck fractures complicating Gaucher disease in children. *Skeletal Radiol.* 12: 162- 8.

Goldstein J, Brown M, Anderson R, Russell D and Schneider W (1985). Receptor-mediated endocytosis: concepts emerging from the LDL receptor system. *Ann Rev of Cell Bio.* 1: 1-39.

Gonzalez-Noriega, A, Grubb J, Talkad V and Sly W (1980). Chloroquine inhibits lysosomal enzyme pinocytosis and enhances lysosomal enzyme secretion by impairing receptor recycling. *J of Cell Bio.* 85: 839-852.

Gort L, Santamaria R, Grinberg D, Vilageliu L, et al. (2007). ‘Identification of a novel pseudodeficiency allele in the GLB1 gene in a carrier of GM1 gangliosidosis’. *Clin Genet.* 72: 109-111.

Gort L, Santamaria R, Grinberg D, Vilageliu L. et al. (2007). ‘Identification of a novel pseudodeficiency allele in the GLB1 gene in a carrier of GM1 gangliosidosis’. *Clin. Genet.* 72: 109 – 111.

Grabowski G (1997). Gaucher disease: gene frequencies and genotype/phenotype correlations. *Genet Test.* 1: 5-12.

Grabowski G & Horowitz M (1997). Gaucher's disease: molecular, genetic, and enzymological aspects. *Baillieres Clin. Haematol.* 10: 635-656.

Grabowski G A (1993). Gaucher disease-Enzymology, genetics, and treatment. *AAAdv Hum Genet.* 21: 377-441.

Grabowski G, Ponce E, Leonova T and Qi X (1997). Clinical and basic studies of enzyme and gene therapy in Gaucher disease type 1. *Japanese J of Inh Metabolic dis.* 43: 283-292.

Grabowski GA (1997). Gaucher disease: gene frequencies and genotype/ phenotype correlations. *Genet Test.* 1: 5-12.

Grabowski GA, Horowitz M (1997). Gaucher's disease: molecular, genetic and enzymological aspects. In: Zimran A, ed. *Gaucher's Disease.* Baillieres Clin Haematol. London: Bailliere Tindall. pp. 635–656.

Grace M, Newman K, Scheinker V, Berg-Fussman A and Grabowski G (1994). Analysis of human acid β -glucosidase by site-directed mutagenesis and heterologous expression. *J Biol Chem.* 269: 2283-2291.

Graves PN, Grabowski GA, Eisner R, Palese P, Smith FI (1988). Gaucher disease type 1: cloning and characterization of a cDNA encoding acid beta-glucosidase from an Ashkenazi Jewish patient. *DNA.* 7: 521-528.

Grossi S, Regis S, Rosano C, Corsolini F et al. (2008). 'Molecular analysis of ARSA and PSAP genes in twenty-one Italian patients with metachromatic leukodystrophy: Identification and functional characterization of 11 novel ARSA alleles'. *Hum Mutat.* 29: E220-E230.

Guo Y, He W, Boer A et al. (1995). Elevated plasma chitotriosidase activity in various lysosomal storage disorders. *J Inherit Metab Dis.* 18: 717-22.

Harmanci O, Bayraktar Y (2008). Gaucher disease: new developments in treatment and etiology. *World J Gastroenterol.* 14: 3968-73.

He G, Grace M, Grabowski G (1992). Gaucher disease: four rare alleles encoding F213I, P289L, T323I, and R463C in type 1 variants, *Hum Mutat.* 1: 423-427.

He GS, Grace ME, Grabowski GA. (1992). Gaucher disease: four rare alleles encoding F213I, P289L, T323I, and R463C in type 1 variants. *Hum Mutat.* 1:423–427.

Heitner R, Elstein D, Aerts J, Weely S, Zimran A (2002). Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. *Blood Cells Mol Dis.* 28: 127-133.

Henrissat B and Bairoch A (1993). New families in the classification of glycosyl hydrolases based on amino acid sequence similarities. *Biochem J.*293: 781-788.

Henrissat B and Bairoch A (1996). Updating the sequence-based classification of glycosyl hydrolases. *Biochem J.*316: 695-696.

Herbert C, Phipps P, Strane R (1974).In *Methods in microbiology*.New York, Academic Press.5: 209.

Hers H (1963). α -Glucosidase deficiency in generalized glycogen storage disease (Pompe's disease). *Biochem J.* 86: 11-16.

Hickman S and Neufeld E (1972). A hypothesis for I-cell disease: defective hydrolases that do not enter lysosomes. *Biochem and Biophys Res Communications.* 49: 992-999.

Ho M, Seck J, Schmidt D, et al. (1972). Adult Gaucher's disease: kindred studies and demonstration of a deficiency of acid, β -glucosidase in cultured fibroblasts. *Am J Hum Genet.* 24: 37-45.

Hobbs JR, Jones KH, Shaw PJ, Lindsay I, Hancock M (1987).Beneficial effect of pre-transplant splenectomy on displacement bone marrow transplantation for Gaucher's syndrome.*Lancet.* 1: 1111-5.

Hodanova K, Hrebicek M, Cervenкова M, Mrazova L, Veptrekova L, Zeman J (1999).Analysis of the β -glucocerebrosidase gene in Czech and Slovak Gaucher patients: Mutation profile and description of six novel mutant alleles. *Blood Cells Mol Dis.* 25: 287-298.

Hoffmann B, Georg Koch H, Schweitzer-Krantz S, Wendel U, et al. (2005).

‘Deficient alpha-galactosidase A activity in plasma but no Fabry disease -A pitfall in diagnosis’. Clin Chem Lab Med. 43: 1276-1277.

Hollak C, Hughes D, Schaik IN, Schwierin B, Bembi B (2009). Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme. Pharmacol Epidemiol Drug Saf. 18: 770-777.

Hollak C, Weely S, Oers M, et al. (1994). Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest. 93: 1288-92.

Hollak CEM, Maas M, Aerts JM (2001). Clinically relevant therapeutic endpoints in type I Gaucher disease. J Inher Metab Dis. 24: 97-105.

Hollak CEM, van Weely S, van Oers MHJ, Aerts JMFG (1994). Marked elevation of plasma chitotriosidase activity: a novel hallmark of Gaucher disease. J Clin Invest. 93:1288-1292.

Hong CM, Ohashi T, Yu XJ, Weiler S, Barranger JA (1990). Sequence of two alleles responsible for Gaucher disease. DNA Cell Biol. 9: 233-241.

Hopp T and Woods K (1981). Prediction of protein antigenic determinants from amino acid sequences. Proc Natl Acad Sci. USA. 78: 3824–3828.

Horowitz M, Tzuri G, Eyal N, Berebi A, Kolodny E, Brady R et al. (1993). Prevalence of Nine Mutations among Jewish and Non-Jewish Gaucher Disease Patients. Am J Hum Genet. 53: 921-930.

Horowitz M, Wilder S, Horowitz Z, et al. (1989). The human glucocerebrosidase gene and pseudogene structure and evolution. Genomics. 4: 87-96.

Horowitz M, Wilder S, Horowitz Z, Reiner O, Gelbart T, Beutler E (1989). The human glucocerebrosidase gene and pseudogene: structure and evolution. Genomics. 4: 87-96.

Horowitz M, Zimran A (1994). Mutations causing Gaucher disease. Hum Mutat. 3: 1-11.

Hruska K, LaMarca M, Scott C & Sidransky E (2008). Gaucher disease: mutation

and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat. 29: 567-583.

Hultberg B, Sjoblad S, Ockerman P (1973). 4-Methylumbelliferyl-, β glucosidase in cultured human fibroblasts from controls and patients with Gaucher's disease. Clin Chim Acta.49: 93-97.

Ida H, Iwasawa K, Kawame H, Rennert OM, Maekawa K, Eto Y (1995). Characteristics of gene mutations among 32 unrelated Japanese Gaucher patients: absence of the common Jewish 84GG and 1226G mutations. Hum Genet. 95: 717-720.

Ida H, Rennert O, Iwasawa K, Kobayashi M, Eto Y, (1999). Clinical and genetic studies of Japanese homozygotes for the Gaucher disease L444P mutation, Hum. Genet. 105 (1-2): 120-126.

Ida H, Rennert OM, Iwasawa K, Kobayashi M, Eto Y (1999). Clinical and genetic studies of Japanese homozygotes for the Gaucher disease L444P mutation. Hum Genet. 105: 120-126.

Ida H, Rennert OM, Kawame H, Maekawa K, Eto Y (1997). Mutation prevalence among 47 unrelated Japanese patients with Gaucher disease: identification of four novel mutations. J Inherit Metab Dis. 20: 67-73.

Park J, Orvisky E, Tayebi N et al. (2003). Myoclonic epilepsy in Gaucher disease: genotype–phenotype insights from a rare patient subgroup. Pediatr Res. 53: 387-395.

Aerts JMF and Hollak CEM (1997). Plasma and metabolic abnormalities in Gaucher's disease. Bailliere's Clinical Haematology.10: 691-709.

Jahreiss L, Menzies F and Rubinsztein D (2008). The itinerary of autophagosomes: from peripheral formation to kiss-and-run fusion with lysosomes. Traffic. 9: 574-587.

Jalanko A and Braulke T (2009). 'Neuronal ceroid lipofuscinoses'. Biochim Biophys Acta. 1793: 697- 709.

Jarosch E, Lenk U and Sommer T (2003). Endoplasmic reticulum- associated protein degradation. International Rev of Cyto. 223: 39-81.

Jesionek-Kupnicka D, Majchrowska A, Krawczyk J, Wendorff J, Barcikowska M, Lukaszek S and Liberski P (2003). Krabbe disease: an ultrastructural study of globoid cells and reactive astrocytes at the brain and optic nerves. *Folia Neuropathol.*35:155-162.

Kampine J, Brady R, Kanfer J, Feld M, Shapiro D (1967).Diagnosis of Gaucher's disease and Niemann-Pick disease with small samples of venous blood. *Science.* 155:86-88.

Kaplan P, Andersson H, Kacena K, and Yee J (2006). “The clinical and demographic characteristics of nonneuronopathic Gaucher Disease in 887 children at diagnosis”.*Arch of Pediatr and Adolescent Med.* 160: 603-608.

Kaplan P, Mazur A, Manor O, et al. (1996). Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. *J Pediatr.*129: 149-153.

Katz K, Cohen I, Ziv N, et al. (1987). Fractures in children who have Gaucher disease. *J Bone Joint Surg Am.* 69:1361-70.

Katz K, Sabato S, Horev G, et al. (1993). Spinal involvement in children and adolescents with Gaucher disease. *Spine.* 18: 332- 5.

Kawame H, Eto Y (1991). A new glucocerebrosidase-gene missense mutation responsible for neuronopathic Gaucher disease in Japanese patients. *Am J Hum Genet.* 49: 1378-1380.

Kawame H, Hasegawa Y, Eto Y, Maekawa K (1992). Rapid identification of mutations in the glucocerebrosidase gene of Gaucher disease patients by analysis of single-strand conformation polymorphisms. *Hum Genet.* 90: 294-296.

Kawame H, Maekawa K, Eto Y (1993). Molecular screening of Japanese patients with Gaucher disease: phenotypic variability in the same genotypes. *Hum Mutat.* 2: 362-367.

Klibansky C, Hoffman J, Zaizov R, Matoth Y (1974). Gaucher's disease, chronic adult type: a comparative study of glucocerebroside and methyl-umbelliferyl-glucopyranoside cleaving potency in leukocytes. *Biomed.* 20: 24-30.

Kocher M, Hall J (2000).Surgical management of spinal involvement in children and adolescents with Gaucher's disease. *J Pediatr Orthop.* 20: 383-8.

Kopitz J, Arnold A, Meissner T and Cantz M (1993). Protein catabolism in fibroblasts cultured from patients with mucopolipidosis II and other lysosomal disorders. *Biochem J.* 295: 577-580.

Koprivica V, Stone D, Park J, Callahan M, Frisch A, Cohen I, et al. (2000).Analysis and Classification of 304 Mutant Alleles in Patients with Type 1 and Type 3 Gaucher Disease.*Am J Hum Genet.*66: 1777-1786.

Kornfeld S and Sly W (2001). 'I-cell disease and pseudo-Hurler polydystrophy: Disorders of lysosomal enzyme phosphorylation and localization', in: Scriver, C.R. et al. (eds), *The Metabolic and Molecular Bases of Inherited Diseases*' (8th edn), McGraw-Hill, New York, NY. 3469-3505.

Kornhaber G, Tropak M, Maegawa G, et al. (2008). Isofagomine induced stabilization of glucocerebrosidase. *Chembiochem.* 9: 2643- 2649.

Kumar P, Henikoff S & Ng P (2009). Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc.* 4: 1073-1082.

Kyllerman M, Conradi N, Mansson J, et al. (1990).Rapidly progressive type III Gaucher disease deterioration following partial splenectomy. *Acta Paediatrica Scandinavica.* 79: 448-453.

L Wan, C M Hsu, C H Tsai et al. (2006). Mutation analysis of Gaucher diseasepatients in Taiwan: high prevalence of the RecNciI and L444P mutations.*Blood Cells Mol Diseases.*36: 422-425.

Lake B, Young E, Winchester B (1198).Prenatal diagnosis of lysosomal storage diseases. *Brain Pathol.* 8: 133-149.

Lamanna W, Lawrence R, Sarrazin S and Esko J (2011).Secondary stor- age of dermatan sulfate in Sanfilippo disease.*J Biol Chem.* 286: 6955-6962.

LaMarca ME, Lieber DS, Portnoy ME, Hruska KS, Green ED, Sidransky E.

(2004).Multi-species comparative sequence analysis of the glucocerebrosidase gene locus. *Am J Hum Genet* 74:A1579.

Laoag-Fernandez J, Fernandez A, Maruo T (2000).Antenatal use of ambroxol for the prevention of infant respiratory distress syndrome.*J Obstet Gynaecol Res.* 26: 307-312.

Latham T, Grabowski GA, Theophilus BD, Smith FI (1990). Complex alleles of the acid beta-glucosidase gene in Gaucher disease. *Am J Hum Genet.* 47: 79-86.

Latham TE, Theophilus BD, Grabowski GA, Smith FI (1991). Heterogeneity of mutations in the acid beta-glucosidase gene of Gaucher disease patients. *DNA Cell Biol.* 10: 15-21.

Lee R (1968).The fine structure of the cerebroside occurring in Gaucher's disease.Proceedings of the National Academy of Sciences of the United States of America.61: 484-489.

Lee R (1996). Necrotic lesions in Gaucher disease: a perspective in the era of enzyme therapy. *Gaucher Clin Perspectives.* 4: 5-10

Lieb H (1924).Cerebroside speicherung bei Splenomegalie Typus Gaucher. *Ztschr. Physiol Chem.* 140: 305-313.

Loeb H, Tondeur M, Jonniaux G, Mockel-Pohl S and Vamos-Hurwitz E (1969).Biochemical and ultrastructural studies in a case of mucopolysaccharidosis "F" (fucosidosis).*Helvetica Paediatr Acta.*24: 519-537.

Long GL, Winfield S, Adolph KW, Ginns EI, Bornstein P. (1996). Structure and organization of the human metaxin gene (MTX) and pseudogene.*Genomics.* 33:177–184.

Lowry OH, Rosenbrough NJ, Farr AL, Randall (1951).Protein measurement with the folin phenol reagent. *J Biol Chem.* 193: 265-275.

Lualdi S, Tappino B, Di Duca M, Dardis A, et al. (2010).‘Enigmatic in vivo iduronate-2-sulfatase (IDS) mutant transcript correction to wild-type in Hunter syndrome’. *Hum Mutat.* 31:1261-1285.

Lukina E, Watman N, Avila Arreguin E, et al. (2010). Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: two-year results of a phase 2 study. *Blood*. 116: 4095-4098.

Lutsky K and Tejwani N (2007).Orthopaedic Manifestations of Gaucher Disease.*Bulletin of the NYU Hospital for Joint Diseases*.65: 37-42.

Luzio J, Pryor P and Bright N (2007). Lysosomes: fusion and function. *Nat Rev Mol Cell Biol*. 8: 622-632.

Luzio J, Rous B, Bright N, Pryor P, Mullock B and Piper R (2000).Lysosome-endosome fusion and lysosome bio- genesis.*J of Cell Sci*. 113: 1515-1524.

Maegawa G, Tropak M, Buttner J, et al. (2009). Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. *J Biol Chem*. 284: 23502-23516.

Magalhaes J, Sa Miranda MC, Pinto R, Lemos M, Poenaru L (1984b). Sodium taurocholate effect on p-glucosidase activity: a new approach for identification of Gaucher disease using the synthetic substract and leucocytes. *Clin Chim Acta*.141: 111-118.

Malaguarnera L (2006). Chitotriosidase: the yin and yang. *Cell Mol Life Sci*. 63: 3018-29.

Mankin H, Rosenthal D, Xavier R (2001). Gaucher Disease: New approaches to an ancient disease. *J Bone Joint Surg Am*. 83: 748-62.

Mark B, Vocadlo D, Knapp S, Triggs-Raine B, Withers S and James M (2001).Crystallographic evidence for substrate-assisted catalysis in a bacterial β -hexosaminidase.*J Biol Chem*.276: 10330-10337.

Mc Master M, Radinns N (1977).Preparation of 6-³H glucocerebroside.*J Labelled Compounds and Radiopharmaceuticals*.13: 353-357.

McEachern K, Fung J, Komarnitsky S, et al. (2007). A specific and potent inhibitor of glucosylceramide synthase for substrate reduction therapy of Gaucher disease. *Mol*

Genet Metab.91: 259-267.

Meikle P, Hopwood J, Clague A, et al. (1999).Prevalence of lysosomal storage disorders.J Am Med Soc. 281: 249-254.

Michelakakis, H., Dimitriou, E., Tsagaraki, S., Giouroukos, S. et al. (1995).‘Lysosomal storage diseases in Greece’. Genet Couns. 6: 43-47.

Miller SA, Dykes DD, Polesky HF (1998).A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16: 1215.

Mistry P, Cox T (1993). The glucocerebrosidase locus in Gaucher's disease: molecular analysis of a lysosomal enzyme. J Med Genet.30: 889-894.

Mistry PK (1995).Genotype/phenotype correlations in Gaucher’s disease. Lancet. 346: 982-983.

Mistry PK (1999). Gaucher’s disease: a model for modern management of a genetic disease. J Hepatol. 30:1-5.

Mistry PK, Abrahamov A (1997).A practical approach to diagnosis and management of Gaucher's disease. Baillieres Clin Haematol. 10: 817-838.

Mistry PK, Lukina E, Ben Turkia H, Amato D, Baris H, Dasouki M, et al (2015). Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. JAMA. 313:695–706.

Moran D, Galperin E and Horowitz M (1997).Identification of factors regulating the expression of the human glucocerebrosidase gene. Gene. 194: 201-213.

Morel N, Bon S, Greenblatt H, Wodak S, Sussman J, Massoulié J and Silman I (1999).Effect of mutations in the peripheral anionic site on the stability of acetylcholinesterase.Mol Pharmacol.55: 982-992.

Morgan A, Platt F, Lloyd-Evans E and Galione A (2011).Molecular mechanisms of endolysosomal Ca²⁺ signalling in health and disease.Biochem J.439: 349–374.

Mullock B, Bright N, Fearon C, Gray S and Luzio J (1998). Fusion of lysosomes with late endosomes produces a hybrid organelle of intermediate density and is NSF

dependent. J Cell Biol. 140: 591-601.

Muschol N, Matzner U, Tiede S, Gieselmann V, Ullrich K and Braulke T (2002). Secretion of phosphomannosyl-deficient arylsulphatase A and cathepsin D from isolated human macrophages. Biochem J. 368: 845-853.

Nagral A (2014). Gaucher Disease. J Clin Exp Hepatol. 4: 37-50.

Natowicz MR, Prenc EM (1996). Heterozygote screening for Tay-Sachs disease: past successes and future challenges. Curr Opin Pediatr.8:625-629.

Nilsson O, Mansson Je, Hakansson G and Svennerholm L (1982). The occurrence of psychosine and other glycolipids in spleen and liver from the three major subtypes of Gaucher's disease. Biochimica et Biophysica Acta. 712: 453-463.

Nishimoto J, Inui K, Okada S, Ishigami W, et al. (1988). 'A family with pseudodeficiency of acid alpha-glucosidase'. Clin Genet. 33: 254-261.

Nixon R, Yang D and Lee J (2008). Neurodegenerative lysosomal disorders: a continuum from development to late age. Autophagy. 4: 590-599.

Novakovic I, Maksimovic N, Cvetkovic S (2010). Gene polymorphisms as marker of disease susceptibility. J Med Biochem.29: 135-8.

Novikoff A (1973). Lysosomes A personal account. In: Lysosomes and Storage Diseases (ed. by H.G. Hers & F. Van Hoof). Academic Press, New York. 2-41.

Nyholm P, Pascher I and Sundell S (1990). The effect of hydrogen bonds on the conformation of glycosphingolipids. Methylated and unmethylated cerebroside studied by X-ray single crystal analysis and model calculations. Chem Phys Lipids.52: 1-10.

O'Brien J, Kretz K, Dewji N, Wenger D, et al. (1988). 'Coding of two sphingolipid activator proteins (SAP-1 and SAP-2) by same genetic locus'. Science. 41: 1098-1101.

Oberling C and Woringer P (1927). La maladie de Gaucher chez le nourrisson, Revue Francais. de Pédiatric. 3: 475-532.

Ockerman P, and Kohlin P (1968).Tissue acid hydrolase activities in Gaucher's disease.Scand J Clin Lab Invest.22: 62-64.

Olivova P, van der Veen K, Cullen E, et al. (2009).Effect of sample collection on alpha-galactosidase a enzyme activity measurements in dried blood spots on filter paper. Clinica Chimica Acta.403: 159-162.

Orengo C, Michie A, Jones S, Jones D, Swindells M and Thornton J (1997). CATH—a hierarchic classification of protein domain structures. Structure. 5: 1093-1108.

Orsi A, Polson H and Tooze S (2010).Membrane trafficking events that partake in autophagy.Curr Opin Cell Biol. 22: 150-156.

Palmieri M, Impey S, Kang H, Ronza A, Pelz C, Sardiello M and Ballabio A (2011). Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways. Hum Mol Genet.20: 3852-3866.

Parenti G (2009). ‘Treating lysosomal storage diseases with pharmacological chaperones: From concept to clinics’. EMBO Mol Med. 1: 268-279.

Park JK, Orvisky E, Tayebi N, Kaneski C, Lamarca ME, Stubblefield BK, Martin BM, Schiffmann R, Sidransky E. (2003). Myoclonic epilepsy in Gaucher disease: genotype-phenotype insights from a rare patient subgroup. Pediatr Res. 53:387–395.

Parkin J and Brunning R (1982). Pathology of the Gaucher cell. Progress in Cli and Bio Res. 95: 151-175.

Pasmanik-Chor M, Laadan S, Elory-stein O, et al. (1996). The Glucocerebrosidase D409H mutation in Gaucher disease. Biochem and Mol Med. 59: 125-133.

Pastores G and Hughes DA, “Gaucher disease,” in *GeneReviews*, R A Pagon, T D Bird, C R Dolan, and K Stephens, Eds (1993). University of Washington, Seattle, Seattle, Wash, USA.

Pastores G, Einhorn T (1995). Skeletal complications of Gaucher disease: pathophysiology, evaluation and treatment. Semin Hematol. 32: 20-7.

Pastores G, Wallenstein S, Desnick R, et al. (1996). Bone density in Type 1 Gaucher disease. *J Bone Miner Res.* 11:1801- 7.

Pastores GM, Petakov M, Giraldo P, et al (2014). A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase. *Blood Cells Mol Dis.*53:253–260.

Patterson M, Horowitz M, Abel R, et al. (1993). Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher's disease. *Neurology.* 43: 1993-1997.

Peters S, Coyle P, and Glew R (1976).Differentiation of β -glucocerebrosidase from β -glucosidase in human tissues using sodium taurocholate.*Arch Biochem Biophys.* 175: 569-582.

Peters S, Lee R, Glew R (1975).A microassay for Gaucher's disease.*Clin Chim Acta.*60: 391-396.

Pinto R, Caseiro C, Lemos M, et al. (2004).Prevalence of lysosomal storage diseases in Portugal.*Eur J Hum Genet.*12: 87-92.

Piraud M, Boyer S, Mathieu M, Maire I (1993). Diagnosis of mucopolysaccharidoses in a clinically selected population by urinary glycosaminoglycan analysis: a study of 2,000 urine samples. *Clin Chim Acta.*221: 171-181.

Platt F and Walkley S (2004).Lysosomal defects and storage.*Lysosomal Disorders of the Brain.*Platt F and Walkley S, editors.Oxford University Press, Oxford. 32-49.

Platt F, Boland B, and Spoel A(2012). Lysosomal storage disorders: The cellular impact of lysosomal dysfunction. *J. Cell Biol.* 199: 723–734

Platt FM, Jeyakumar M. Substrate reduction therapy (2008).*Acta Paediatr.* 97:88–93.

Ponce E, Mear J and Grabowski G (1994). Gaucher disease: pseudoverion of a

disease mutations effects- Implications for structure-function and genotype/phenotype correlations. Am J of Hum Genet. 55: A

Poorthuis, B.J., Wevers, R.A., Kleijer, W.J., Groener, J.E. et al. (1999). ‘The frequency of lysosomal storage diseases in The Netherlands’, Hum Genet.105: 151-156.

Poupetova H, Ledvinova J, Berna L et al. (2010). The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations. J Inherit Metab Dis. 33: 387-396.

Prinetti A, Prioni S, Chiricozzi E, Schuchman E, Chigorno V, and Sonnino S (2011). Secondary alterations of sphingolipid metabolism in lysosomal storage diseases. Neurochem Res. 36: 1654-1668.

Radin N (1976). Chemical models and chemotherapy in the sphingolipidoses. Volk B, Schneck L, eds. Current Trends in Sphingolipidoses and Allied Disorders. New York, NY: Plenum Press. 453.

Raghavan S, Topol J, and Kolodny E (1980). Leukocyte β -glucosidase in homozygotes and heterozygotes for Gaucher’s disease. Am J Hum Genet. 32: 158-173.

Ramensky V, Bork P and Sunyaev S (2002). Human non-synonymous SNPs: server and survey. Nucleic Acids Res. 30: 3894-3900.

Reddy A, Caler E and Andrews N (2001). Plasma membrane repair is mediated by Ca (2+)-regulated exocytosis of lysosomes. Cell. 106: 157-169.

Reiner O, Wigderson M, Horowitz M (1988). Structural analysis of the human glucocerebrosidase genes. DNA.7: 107-116.

Reinner O and Horowitz M (1988). Differential expression of the human glucocerebrosidase- coding gene. Gene. 73: 469-478.

Reinner O, Wigderson M and Horowitz M (1988a). Structural analysis of the human glucocerebrosidase gene. DNA. 7: 107-116.

Reinner O, Wigderson M and Horowitz M (1988b). Characterization of the normal

human glucocerebrosidase gene and a mutated form in Gaucher's patient. In Salvayre R, Douste-Blazy L and Gatt S (eds) Lipid Storage Disorders. Biological and Medical aspects. New York: Plenum Press. 29-39.

Reitman M and Kornfeld S (1981). UDP-N-acetylglucosamine: glycoprotein N-acetylglucosamine-1-phosphotransferase. Proposed enzyme for the phosphorylation of the high mannose oligo- saccharide units of lysosomal enzymes. J of Bio Chem. 256: 4275-4281.

Renkema G, Boot R, Muijsers A, Donker-Koopman W and Aerts J (1995). J Biol Chem. 270: 2198-2202.

Renkema G, Boot R, Strijland A, Donker-koopman W, Berg M, Muijsers A and Aerts J (1997). Eur J Biochem. 244: 279-285.

Ringdén O, Groth C, Erikson A, et al. (1995). Ten years experience of bone marrow transplantation for Gaucher disease. Transplantation. 59: 864-870.

Rodrigue S, Rosenthal D, Barton N, et al. (1999). Risk factors for osteonecrosis in patients with type 1 Gaucher's disease. Clin Orthop Relat Res. 362: 201-7.

Rozenberg R, Fox DC, Sobreira E, Pereira LV (2006). Detection of 12 new mutations in Gaucher disease Brazilian patients. Blood Cells Mol Dis. 37: 204-209.

Ruiz J, Barzegar S, Clarke A, et al. (2010). Antigenic differences in patients receiving velaglucerase alfa or imiglucerase. Presented at the 6th Annual Lysosomal Disease Network World Symposium, Miami, FL. 10-12.

Saftig P and Klumperman J (2009). Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function. Nat Rev Mol Cell Biol. 10: 623-635.

Sambrook J, Fritsch EF, Maniatis T (1989). Molecular Cloning: A laboratory Manual. 2nd Edition. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press.

Sandhoff K, Kolter T and Harzer K (2001). 'Sphingolipid activator proteins', Scriver C et al. (eds), The Metabolic and Molecular Bases of Inherited Diseases' (8th edn), McGraw-Hill, New York, NY. 3371-3388.

Santavuori P (1988). ‘Neuronal ceroid-lipofuscinoses in childhood’, Brain Dev. 10: 80-83.

Sardiello M, Palmieri M, Ronza A, Medina D, Valenza M, Gennarino V, Malta C, Donaudy F, Embrione V, Polishchuk R, et al. (2009). A gene network regulating lysosomal biogenesis and function. Science. 325: 473-477.

Sarria AJ, Giraldo P, Perez-Calvo JI, Pocovi M (1999). Detection of three rare (G377S, T134P and 1451delAC), and two novel mutations (G195W and Rec 1263del55; 1342G>C) in Spanish Gaucher disease patients. Mutation in Brief 251. Online. Hum Mutat 14: 88.

Sawkar A, Cheng W, Beutler E, Wong C, Balch W & Kelly J (2002). Chemical chaperones increase the cellular activity of N370S β -glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci USA. 99: 15428-15433.

Schiffmann R (2010). ‘Therapeutic approaches for neuronopathic lysosomal storage disorders’. J Inherit Metab Dis. 33: 373-379.

Schiffmann R, Fitzgibbon E, Harris C, et al. (2008). Randomized, controlled trial of miglustat in Gaucher’s disease type 3. Ann Neurol. 64: 514-522.

Schiffmann R, Heyes M, Aerts J, et al. (1997). Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher disease. Annals of Neurology. 42: 613-621.

Schuchman EH, Miranda SR (1997). Niemann-Pick disease: mutation update, genotype/phenotype correlations, and prospects for genetic testing. Genet Test. 1:13-19.

Schwarz JM, Rodelsperger C, Schuelke M, Seelow D (2010). Mutation Taster evaluates disease-causing potential of sequence alterations. Nat Methods. 7: 575-576.

Sechi A, Dardis A, Bembi B (2016). Profile of eliglustat tartrate in the management of Gaucher disease. Therapeutics and Clinical Risk Management 12: 53–58

Sechi A, Deroma L, Dardis A, et al (2014). Long term effects of enzyme replacement therapy in an Italian cohort of type 3 Gaucher patients. Mol Genet

Metab.113:213–218.

Seinsheimer F, Mankin H (1977). Acute bilateral symmetrical pathologic fractures of the lateral tibial plateaus in a patient with Gaucher's disease. *Arthritis Rheum.* 20:1550- 5.

Shaaltiel Y, Bartfeld D, Hashmueli S, et al. (2007). Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. *Plant Biotechnol J.* 5: 579-590.

Shapiro B, Logigian E, Kolodny E, and Pastores G (2008). Late-onset Tay-Sachs disease: the spectrum of peripheral neuropathy in 30 affected patients. *Muscle Nerve.* 38: 1012-1015.

Shapria E, Blitzer MG, Miller JB et al. (1989). Fluorometric assays in *Biochemical Genetics: A laboratory Manual* Oxford university press. 19-46.

Sheth J, Ankleshwaria C, Mistri M, Nanavaty N, and Mehta S (2011). Splenomegaly, Cardiomegaly, and Osteoporosis in a Child with Gaucher Disease. *Case Reports in Pediatrics* Article ID 564868, 4 pages doi: 10.1155/2011/564868

Sheth J, Mistri M, Sheth F, Shah R, Bavdekar A, Godbole K, et al. (2013). Burden of lysosomal storage disorders in India: Experience of 387 affected children from a single diagnostic facility. *JIMD Reports.* 12: 51-63.

Sheth J, Patel P, Sheth F, Shah R (2004). Lysosomal storage disorders. *Indian Pediatr.* 41: 260-265.

Sheth J, Sheth F, Oza N, Gambhir P, Dave U, Shah R (2010). Plasma chitotriosidase activity in children with lysosomal storage disorders. *Indian J Pediatr.* 77: 203-5.

Sibille A, Eng CM, Kim SJ, PastoresG, Grabowski GA (1993). Phenotype/genotype correlations in Gaucher disease type I: clinical and therapeutic implications. *Am J Hum Genet.* 52: 1094-1101.

Sidransky E, Bottler A, Stubblefield B, Ginns EI (1994). DNA mutational analysis

of type 1 and type 3 Gaucher patients: how well do mutations predict phenotype? Hum Mutat. 3: 25-28.

Sidransky E, Lau E, Winfield S, et al. (1997). Identification of two novel polymorphisms in the glucocerebrosidase gene region. Am J of Hum Genet.

Siebert M, Bock H, Michelin-Tirelli K, Coelho J, Giugliani R, Saraiva Pereira M (2012). Novel Mutations in the Glucocerebrosidase Gene of Brazilian Patients with Gaucher Disease. JIMD Reports. DOI 10.1007/8904_2012_174.

Skoog W and Beck W (1956). Studies on the fibrinogen, dextran and phytohemagglutinin methods of isolating leukocytes. Blood. 11: 436-454.

Smidt-Jensen S, Lind A, Permin M, Zachary J, Lundsteen C, Philip J (1993). Cytogenetic analysis of 2928 CVS samples and 1075 amniocenteses from randomized studies. Prenat Diagn. 13: 723-40.

Sorge J, West C, Westwood B, Beutler E (1985b). Molecular cloning and nucleotide sequence of human glucocerebrosidase cDNA. Proc Natl Acad Sci USA. 82: 7289-7293.

Spada M, Pagliardini S, Yasuda M, Tükel T, Thiagarajan G, Sakuraba H, Ponzzone A, and Desnick R (2006). High incidence of later onset fabry disease revealed by newborn screening. Am J Hum Genet. 79: 31-40.

Spiegel R, Bach G, Sury V, Mengistu G, et al. (2005). ‘A mutation in the saposin A coding region of the prosaposin gene in an infant presenting as Krabbe disease: First report of saposin A deficiency in humans’. Mol Genet Metab. 84: 160-166.

Staretz-Chacham O, Lang T, LaMarca M, et al. (2009). Lysosomal storage disorders in the newborn. Pediatr. 123: 1191-207.

Stowens D, Teitelbaum S, Kahn A, Barranger J (1985). Skeletal complications of Gaucher disease. Med (Baltimore). 64: 310-22.

Strasberg PM, Warren I, Skomorowski MA, Lowden JA (1983). HPLC analysis of neutral glycolipids: an aid in the diagnosis of lysosomal storage disease. Clinica Chimica Acta. 132: 29-41.

Suzuki K (1982). Glucosylceramide and related compounds in normal tissues and in Gaucher disease. In Desnick R, Gatt S and Grabowski G (eds) Gaucher disease: a century of Delineation and research. New York: Alan R Liss. 219-230.

Svennerholm L, Hakansson G, Mansson J and Nilsson O (1982). Chemical differentiation of the Gaucher subtypes. In Desnick R, Gatt S and Grabowski G (eds) Gaucher disease: a century of Delineation and research. New York: Alan R Liss. 231-252.

Tammachote R, Tongkobpetch S, Srichomthong C, Phipatthanantanti K, Pungkanon S, Wattanasirichaigoon D et al. (2013). A common and two novel GBA mutations in Thai patients with Gaucher disease. J Hum Genet.58: 594-599.

Tauber C, Tauber T (1995).Gaucher disease the orthopaedic aspect.Report of seven cases. Arch Orthop Trauma Surg. 114: 179-82.

Tayebi N, Stubblefield BK, Park JK, Orvisky E, Walker JM, LaMarca ME, Sidransky E (2003). Reciprocal and nonreciprocal recombination at the glucocerebrosidase gene region: implications for complexity in Gaucher disease. Am J Hum Genet.72: 519-534.

Terry R and Weiss M (1963).Studies in Tay-Sachs disease II.Ultra- structure of the cerebrum.J of Neuropathology and Exper Neurology. 22: 18-55.

Teshima IE, Kalousek DK, Vekemans MJ, Markovic V, Cox DM, Dallaire L, et al. (1992).Canadian multicenter randomized clinical trial of chorion villus sampling and amniocentesis. chromosome mosaicism in CVS and amniocentesis samples. Prenat Diagn. 12: 443-66.

Thomas G (1994).‘Pseudodeficiencies” of lysosomal hydrolases’.AmJ Hum Genet. 54: 934-940.

Tjelle T, Brech A, Juvet L, Griffiths G, and Berg T (1996). Isolation and characterization of early endosomes, late endosomes and terminal lysosomes: their role in protein degradation. J Cell Sci. 109: 2905-2914.

Tsai F, Lee C, Wu M, Lin S, Lin C, Tsai C et al. (2001). Mutation analysis of type

II Gaucher disease in five Taiwanese children: identification of two novel mutations. *Acta Paediatr Taiwan*.42: 231-235.

Tsuji S, Choudary PV, Martin BM, Stubblefield BK, Mayor JA, Barranger JA, Ginns EI (1987).A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher's disease. *N Engl J Med*. 316: 570-575.

Tsuji S, Martin BM, Barranger JA, Stubblefield BK, LaMarca ME, Ginns EI (1988).Genetic heterogeneity in type 1 Gaucher disease: multiple genotypes in Ashkenazic and non-Ashkenazic individuals. *Proc Natl Acad Sci USA*. 85: 2349-2352.

Tylki-Szyman'ska A, Czartoryska B, Vanier M, Poorthuis B, et al. (2007).'Non-neuronopathic Gaucher disease due to saposin C deficiency'. *Clin Genet*. 72: 538-542.

Tylki-Szymanska A, Millat G, Maire I, Czartoryska B (1996). Types I and III Gaucher disease in Poland: incidence of the most common mutations and phenotypic manifestations. *Eur J Hum Genet*.4: 334-337.

Uchiyama A, Tomatsu S, Kondo N, Suzuki Y, Shimozawa N, Fukuda S et al. (1994). New Gaucher disease mutations in exon 10: a novel L444R mutation produces a new NciI site the same as L444P. *Hum Mol Genet*. 3: 1183-1184.

Ullman M and McCluer R (1977).Quantitative analysis of plasma neutral glycosphingolipids by high performance liquid chromatography of their perbenzoyl derivatives. *J of Lipid Res*. 18: 371-378.

Vallance, H. and Ford, J. (2003).'Carrier testing for autosomal-recessive disorders'. *Crit Rev Clin Lab Sci*. 40: 473-497.

Vanier M, Wenger D, Comly M, Rousson R, Brady R and Pentchev P (1988). Niemann-Pick disease group C: clinical variability and diagnosis based on defective cholesterol esterification. A collaborative study on 70 patients. *Clinical Genet*. 33: 331-348.

Varki A and Kornfeld S (1981).Purification and characterization of rat liver alpha-N-acetylglucosaminyl phosphodiesterase. *J of Bio Chem*. 256: 9937-9943.

- Vellodi A (2004).** ‘Lysosomal storage disorders’. *Br J Haematol.* 128: 413-431.
- Vellodi A (2005).** Lysosomal storage disorders. *Br J Haematol.* 128: 413-431 .
- Verma I (2016).** Fetal Medicine in India: Taking Stock of 2015, and Planning for 2016 at the Journal of Fetal Medicine. *J Fetal Med.* 3:1–4.
- Verma P, Rangnath P, Dalal A, et al. (2012).** Spectrum of lysosomal storage disorders at a Medical Genetics Center in North India. *Indian Pediatr.* 49: 799-804.
- Vervoort R, Islam M, Sly W, Chabas A et al. (1995).** ‘A pseudo- deficiency allele (D152N) of the human beta-glucuronidase gene’. *Am J Hum Genet.* 57: 798-804.
- Vitner E, Platt F and Futerman A (2010).** Common and uncommon pathogenic cascades in lysosomal storage diseases. *J Biol Chem.* 285: 20423-20427.
- Vladutiu G and Rattazzi M (1979).** Excretion-reuptake route of β -hexosaminidase in normal and I-cell disease cultured fibro- blasts. *J of Clinical Investigation.* 63: 595-601.
- Waheed A, Hasilik A and von Figura K (1981).** Processing of the phosphorylated recognition marker in lysosomal enzymes. Characterization and partial purification of a microsomal alpha-N-acetylglucosaminyl phosphodiesterase. *J of Bio Chem.* 256: 5717-5721.
- Wajner A, Michelin K, Burin M, et al. (2007).** Comparison between the biochemical properties of plasma chitotriosidase from normal individuals and from patients with Gaucher disease, GM1- gangliosidosis, Krabbe disease and heterozygotes for Gaucher disease. *Clin Biochem.* 40: 365-9.
- Walkley S and Vanier M (2009).** Secondary lipid accumulation in lysosomal disease. *Biochim Biophys Acta.* 1793: 726-736.
- Wan L, Hsu C, Tsai C, Lee C, C Hwu W L & Tsai F J (2006).** Mutation analysis of Gaucher disease patients in Taiwan: high prevalence of the RecNciI and L444P mutations. *Blood Cells Mol. Dis.* 36: 422-425.
- Wang R, Bodamer O, Watson M and Wilcox W (2011).** on behalf of the ACMG

Work Group on Diagnostic Confirmation of Lysosomal Storage Diseases. Lysosomal storage diseases: Diagnostic confirmation and management of presymptomatic individuals. *Genet in Med*. 13: 457-484.

Wauters J, Stuer K, Elsen A and Willems P (1992). ‘ α -L-fucosidase in human fibroblasts. I. The enzyme activity polymorphism’. *Biochem Genet*. 30:131-141.

Weinreb N, Charrow J, Andersson H, et al. (2002). Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. *Am J Med*. 113:112-119.

Weinreb NJ, Goldblatt J, Villalobos J, et al (2013). Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. *J Inherit Metab Dis*. 36:543–553.

Wenger D, Clark C, Sattler M, and Wharton C (1978). Synthetic substrate β -glucosidase activity in leukocytes: A reproducible method for the identification of patients and carriers of Gaucher’s disease. *Clin Genet*. 13: 145-153.

Wenger D, De Gala G, Williams C, Taylor H, et al. (1989). ‘Clinical, pathological, and biochemical studies on an infantile case of sulfatide/GM1 activator protein deficiency’. *Am J Med Genet*. 33: 255 -265.

Wenstrup R, Espiau R, Weinreb J, and Bembi B (2002). Skeletal aspects of Gaucher disease: a review. *The British Journal of Radiology*. The British Institute of Radiology Chapter 1. 75: A2-A12.

Wenstrup RJ, Kacena KA, Kaplan P, et al (2007). Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. *J Bone Miner Res*. 22:119–126.

Westhead D, Slidel T, Flores T and Thornton J (1999). Protein structural topology: automated analysis, diagrammatic representation and database searching. *Protein Sci*. 8: 897-904.

Wilcox W (2004). Lysosomal storage disorders: the need for better pediatric recognition and comprehensive care. *J Pediatr*. 144: S3-S14.

Wilkening G, Linke T and Sandhoff K (1998). Lysosomal degradation on vesicular membrane surfaces—enhanced glucosylceramide degradation by lysosomal anionic lipids and activators. *J Biol Chem.* 273: 30271-30278.

Winchester B (2004). Primary defects in lysosomal enzymes. *In Lysosomal Disorders of the Brain.* Platt F and Walkley S, editors. Oxford University Press, Oxford. 81-130.

Winfield SL, Tayebi N, Martin BM, Ginns EI, Sidransky E. (1997). Identification of three additional genes contiguous to the glucocerebrosidase locus on chromosome 1q21: implications for Gaucher disease. *Genome Res* 7:1020–1026.

Winkelman M, Banker B, Victor M and Moser H (1983). Non-infantile neuronopathic Gaucher's disease : a clinicopathologic study. *Neurology.* 33: 994-1008.

Wraith J (2002). Lysosomal disorders. *Semin Neonatol.* 7: 75-83.

Wraith J (2004). Clinical aspects and diagnosis. *In Lysosomal disorders of the brain.* Platt F and Walkley S, editors. Oxford University Press, Oxford. 50-77.

Yang C, Rahimpour S, Lu J, Pacak K, Ikejiri B, Brady RO, Zhuang Z (2013). Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones. *Proc Natl Acad Sci U S A.* 110:966–71.

Zeman W and Donahue S (1963). Fine structure of the lipid bodies in juvenile amaurotic idiocy. *Acta Neuropathologica.* 3: 144-149.

Zevin S, Abrahamov A, Hadas-Halpern I, et al. (1993). Adult-type Gaucher disease in children. *Q J Med.* 865: 65-573.

Zimran A (1997). Clinical Haematology International practice and Research—Gaucher's disease. Bailliere Tindall, London, UK.

Zimran A (2011). How I treat Gaucher disease. *Blood.* 118: 1463-1471.

Zimran A, Altarescu G, Elstein D (2013). Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. *Blood Cells Mol Dis.* 50:134–7.

Zimran A, Altarescu G, Philips M et al. (2010). Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. *Blood*. 115: 4651-4656.

Zimran A, Loveday K, Fratazzi C, Elstein D (2007). A pharmacokinetic analysis of a novel enzyme replacement therapy with gene-activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease. *Blood Cells Mol Dis*. 39: 115-118.

Zimran A, Sorge J, Gross E, Kubitz M, West C, Beutler E (1990b). A glucocerebrosidase fusion gene in Gaucher disease. Implications for the molecular anatomy, pathogenesis, and diagnosis of this disorder. *J Clin Invest*. 85: 219-222.

Zimran A, Wang N, Ogg C, et al (2015). Seven-year safety and efficacy with velaglucerase alfa for treatment-naïve adult patients with type 1 Gaucher disease. *Am J Hematol*.90: 577-583.